Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06728319 · ClinicalTrials.gov registry record
A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-World
A clinical trial of Lung Nodules, sponsored by Biodesix.
- Active
- Registry status
- 4,000
- Enrollment target
- 5
- Study locations
NCT06728319 is a study of Lung Nodules that is active but no longer recruiting, run by Biodesix. The registered enrollment target is 4,000 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT06728319, a study of Lung Nodules, is active but no longer recruiting, sponsored by Biodesix.
- ACTIVE NOT RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a multicenter retrospective chart review. Sites with at least 100 patients tested with the IC and AAT tests, who have index dates (date of IC and AAT testing) at least one year prior to data collection date will be eligible for participation.
Conditions Studied
Study Locations (5)
Florida
- Pulmonary & Sleep of Tampa Bay - Brandon
- White-Wilson Medical Center - Fort Walton Beach
Kentucky
- The Lung and Sleep Disorder Institute - Somerset
Massachusetts
- Southcoast Health System - Fairhaven
Pennsylvania
- The Lung Center, PC - DuBois
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2027-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06728319
The ClinicalTrials.gov registry entry for NCT06728319 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biodesix, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Nodules appearing as the primary indexed condition, and to 0 interventions.
NCT06728319 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Kentucky, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06728319 about?
NCT06728319 is a clinical study titled "A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-World". This study is a multicenter retrospective chart review. Sites with at least 100 patients tested with the IC and AAT tests, who have index dates (date of IC and AAT testing) at least one year prior to data collection date will be eligible for participation.
What is the current status of trial NCT06728319?
This trial is currently active not recruiting. The enrollment target is 4,000 participants. The study started on 2024-09-19. Estimated completion is 2027-07-31.
What conditions does trial NCT06728319 study?
This clinical trial studies the following conditions: Lung Nodules.
Who is sponsoring clinical trial NCT06728319?
This trial is sponsored by Biodesix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06728319 being conducted?
This trial has 5 study locations across Florida, Kentucky, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Nodules
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.